Citadel Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-154,764
| Closed | -$1.49M | – | 16023 |
|
|
2024
Q4 | $1.49M | Buy |
+154,764
| New | +$807K | ﹤0.01% | 6252 |
|
|
2024
Q2 | – | Sell |
-64,424
| Closed | -$176K | – | 15666 |
|
|
2024
Q1 | $206K | Buy |
+64,424
| New | +$215K | ﹤0.01% | 10273 |
|
|
2023
Q4 | – | Sell |
-746
| Closed | -$1.77K | – | 15458 |
|
|
2023
Q3 | $1.77K | Sell |
746
-87,319
| -99% | -$183K | ﹤0.01% | 13809 |
|
|
2023
Q2 | $155K | Sell |
88,065
-143,439
| -62% | -$366K | ﹤0.01% | 10291 |
|
|
2023
Q1 | $713K | Buy |
231,504
+189,791
| +455% | +$1.14M | ﹤0.01% | 7519 |
|
|
2022
Q4 | $221K | Sell |
41,713
-315,025
| -88% | -$1.44M | ﹤0.01% | 9938 |
|
|
2022
Q3 | $1.26M | Buy |
356,738
+284,164
| +392% | +$940K | ﹤0.01% | 6497 |
|
|
2022
Q2 | $187K | Buy |
72,574
+54,437
| +300% | +$151K | ﹤0.01% | 10773 |
|
|
2022
Q1 | $81K | Sell |
18,137
-6,877
| -27% | -$31K | ﹤0.01% | 12474 |
|
|
2021
Q4 | $170K | Buy |
+25,014
| New | +$170K | ﹤0.01% | 12101 |
|
|
2021
Q3 | – | Sell |
-20,710
| Closed | -$178K | – | 14836 |
|
|
2021
Q2 | $208K | Sell |
20,710
-115,348
| -85% | -$1.03M | ﹤0.01% | 12073 |
|
|
2021
Q1 | $1.3M | Buy |
+136,058
| New | +$1.33M | ﹤0.01% | 7462 |
|
|
2020
Q4 | – | Sell |
-44,515
| Closed | -$395K | – | 11652 |
|
|
2020
Q3 | $395K | Buy |
+44,515
| New | +$507K | ﹤0.01% | 7694 |
|
Other funds holding PSTX
Citadel Advisors's PSTX Position: Q1 2025 in Review
Citadel Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 154,764 shares — an estimated $1.49M sold.
Citadel Advisors first reported a position in PSTX in Q3 2020 and held it in 13 quarters. The position peaked at $1.49M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Citadel Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Citadel Advisors sold 154,764 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.49M.
- Citadel Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 13 quarters.
- Citadel Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $1.49M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.